Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Foley

Showing results (171-180 of 185) with videos related to

Pageof 19
Sort By:
Journal of Cutaneous Medicine and Surgery|April 14, 2017
Structured Expert Consensus on Actinic Keratosis: Treatment Algorithm Focusing on Daylight PDTPiergiacomo Calzavara-Pinton, Merete Hædersdal, Kirk Barber, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
Dermatology and Therapy|February 14, 2025
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of EfficacyJonathan I Silverberg, Thomas Bieber, Amy S Paller, et al.
Multiple Sclerosis and Related Disorders|December 9, 2022
Network analysis characterizes key associations between subjective fatigue and specific depressive symptoms in early relapsing-remitting multiple sclerosisYuan-Ting Chang, Patrick K A Kearns, Alan Carson, et al.
Immunotherapy|September 1, 2025
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical studyStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2024
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitisStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
The Journal of Investigative Dermatology|April 19, 2026
The role of biosimilars in enhancing global access to psoriasis treatmentYasmina Behlock, Sean P Gavan, Thomas Graier, et al.
Brain Communications|October 10, 2024
Fatigue in early multiple sclerosis: MRI metrics of neuroinflammation, relapse and neurodegenerationRozanna Meijboom, Peter Foley, Niall J J MacDougall, et al.
BMJ Open|June 29, 2022
FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosisPatrick K A Kearns, Sarah J Martin, Jessie Chang, et al.
Journal of the American Academy of Dermatology|October 28, 2022
Improving skin cancer management with ARTificial intelligence: A pre-post intervention trial of an artificial intelligence system used as a diagnostic aid for skin cancer management in a real-world specialist dermatology settingClaire Felmingham, Yan Pan, Yonatan Kok, et al.
Pageof 19

Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
Journal of Cutaneous Medicine and Surgery|April 14, 2017
Structured Expert Consensus on Actinic Keratosis: Treatment Algorithm Focusing on Daylight PDTPiergiacomo Calzavara-Pinton, Merete Hædersdal, Kirk Barber, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
Dermatology and Therapy|February 14, 2025
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of EfficacyJonathan I Silverberg, Thomas Bieber, Amy S Paller, et al.
Multiple Sclerosis and Related Disorders|December 9, 2022
Network analysis characterizes key associations between subjective fatigue and specific depressive symptoms in early relapsing-remitting multiple sclerosisYuan-Ting Chang, Patrick K A Kearns, Alan Carson, et al.
Immunotherapy|September 1, 2025
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical studyStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2024
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitisStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
The Journal of Investigative Dermatology|April 19, 2026
The role of biosimilars in enhancing global access to psoriasis treatmentYasmina Behlock, Sean P Gavan, Thomas Graier, et al.
Brain Communications|October 10, 2024
Fatigue in early multiple sclerosis: MRI metrics of neuroinflammation, relapse and neurodegenerationRozanna Meijboom, Peter Foley, Niall J J MacDougall, et al.
BMJ Open|June 29, 2022
FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosisPatrick K A Kearns, Sarah J Martin, Jessie Chang, et al.
Journal of the American Academy of Dermatology|October 28, 2022
Improving skin cancer management with ARTificial intelligence: A pre-post intervention trial of an artificial intelligence system used as a diagnostic aid for skin cancer management in a real-world specialist dermatology settingClaire Felmingham, Yan Pan, Yonatan Kok, et al.
Pageof 19